Drug Trial Radar · NCT06481085
To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
Last checked: Nov 19, 2026Latest source record: Jul 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
324
Actual
Start
Jun 27, 2024
Primary completion
May 30, 2025
Study completion Jun 30, 2025
Sponsor
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo controlled, parallel group study, which aims to provide data on efficacy, safety and pharmacokinetics (PK) of multiple dose levels of HDM1002 tablets in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and/or diet and exercise.
Conditions
- Type 2 Diabetes
Interventions
HDM1002 50 mgDrug
HDM1002 tablets, 50 mg once daily, 12 weeks
HDM1002 100 mgDrug
HDM1002 tablets, 100 mg once daily, 12 weeks
HDM1002 200 mgDrug
HDM1002 tablets, 200 mg once daily, 12 weeks
HDM1002 400 mgDrug
HDM1002 tablets, 400 mg once daily, 12 weeks
HDM1002 200 mg BIDDrug
HDM1002 tablets, 200 mg twice daily, 12 weeks
PlaceboDrug
Matching placebo will be provided
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in HbA1c at Week 12Time frame: Baseline, Week 12
Locations
31 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chaoyang Hospital Affiliated to Capital Medical University
Beijing, China
Peking University Shougang Hospital
Beijing, China
Cangzhou Central Hospital
Cangzhou, China
The Second Hospital of Jilin University
Changchun, China
The Fourth Hospital of Changsha City
Changsha, China
The Third Hospital of Changsha City
Changsha, China
Chengdu Second People's Hospital
Chengdu, China
The Affiliated Hospital of Chengdu University
Chengdu, China
Three Gorges Hospital Affiliated to Chongqing University
Chongqing, China
The First Hospital of Handan City
Handan, China
Zhejiang Provincial People's Hospital
Hangzhou, China
The Fourth Affiliated Hospital of Harbin Medical University
Harbin, China
The Second Affiliated Hospital of Anhui Medical University
Hefei, China
Huizhou Central People's Hospital
Huizhou, China
Huzhou Central Hospital
Huzhou, China
Jinan Central Hospital
Jinan, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, China
The Third People's Hospital of Luoyang City
Luoyang, China
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, China
The First Affiliated Hospital of Nanyang Medical College
Nanyang, China
The First People's Hospital of Nanyang City
Nanyang, China
Panjin Liaohe Oilfield General Hospital
Panjin, China
The First Hospital of Qinhuangdao City
Qinhuangdao, China
Suzhou Municipal Hospital
Suzhou, China
The First Hospital of Shanxi Medical University
Taiyuan, China
Tonghua Central Hospital
Tonghua, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
Xuzhou Cancer Hospital
Xuzhou, China
Yueyang People's Hospital
Yueyang, China
The Second Affiliated Hospital of Zhengzhou University
Zhengzhou, China
The Chinese People's Liberation Army General Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.